Lijie Zhan

This inventor holds 14 USPTO granted patents and 3 published patent applications, plus 5 CIPO patents and 5 EPO patents. Top assignee: Methylgene, Inc.. Active years: 2010-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lijie Zhan. Retrieved from https://idiyas.com/inventor/lijie-zhan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 3)

% Patents Active = 64.3

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 8.7

ph-index = 2

Forward Citations = 22(Granted Patents)

Company Filing History:

14 out of 53

Methylgene, Inc.

patents

Years Active: 2010-2015

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9018378 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2015-04-28),

2. 8907091 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2014-12-09),

3. 8906852 - Inhibitors of protein tyrosine kinase activity (2014-12-09),

4. 8846927 - Inhibitors of protein tyrosine kinase activity (2014-09-30),

5. 8759522 - Inhibitors of protein tyrosine kinase activity (2014-06-24),

6. 8729268 - Inhibitors of protein tyrosine kinase activity (2014-05-20),

7. 8470850 - Inhibitors of VEGF receptor and HGF receptor signalling (2013-06-25),

8. 8455484 - Selected inhibitors of protein tyrosine kinase activity (2013-06-04),

9. 8404846 - Inhibitors of protein tyrosine kinase activity (2013-03-26),

10. 8389541 - Inhibitors of protein tyrosine kinase activity (2013-03-05),

11. 8329726 - Inhibitors of VEGF receptor and HGF receptor signaling (2012-12-11),

12. 8093264 - Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling (2012-01-10),

13. 7790729 - Inhibitors of VEGF receptor and HGF receptor signaling (2010-09-07),

14. 7772247 - Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor (2010-08-10),

Title: Unveiling the Innovation Journey of Inventor Lijie Zhan

Introduction

Inventor Lijie Zhan, based in Montreal, CA, has left a lasting mark in the realm of pharmaceutical innovation with his remarkable work. With a total of 14 patents to his name, Zhan is a trailblazer in the field of developing compounds with significant therapeutic potential.

Latest Patents

Zhan's recent patents showcase his expertise in creating cutting-edge solutions in the pharmaceutical industry. His inventions revolve around processes and intermediates for producing fused heterocyclic kinase inhibitors, particularly thienopyridine-based compounds, aimed at industrial applications. Additionally, his work on inhibitors of protein tyrosine kinase activity, focusing on growth factor receptors, highlights his commitment to combatting cell proliferative and ophthalmic diseases.

Career Highlights

Currently employed at Methylgene, Inc., Zhan has honed his skills and made substantial contributions to the company's innovative endeavors. His role at Methylgene, Inc. underscores his dedication to driving advancements in pharmaceutical research and development.

Collaborations

Zhan's collaborative spirit is exemplified through his partnerships with accomplished professionals like Stephen Claridge and Arkadii Vaisburg. By working closely with experts in the field, Zhan has been able to leverage collective knowledge and experience to create groundbreaking solutions.

Conclusion

In conclusion, Lijie Zhan's inventive prowess and unwavering dedication to advancing pharmaceutical innovation have cemented his position as a key figure in the industry. His keen focus on developing novel compounds for therapeutic purposes underscores his significant contributions to the field. Through his continued efforts, Zhan continues to push boundaries and drive towards transformative breakthroughs in healthcare.

Profile summary based on public USPTO records.